"GSK Portugal wants to work in close collaboration with the authorities to maximize the number of patients treated with our innovative medicines and vaccines"
In Conversation
"Aside from the company’s success, Portugal is a fantastic pilot country. Despite the fact that we face many challenges, the way that we overcome these challenges…
" We must work together in a collaborative spirit to shift the paradigm away from targeting purely low prices and instead, enhance the sustainability of the…
"The biggest difficulty is the market access; I am sure I am not the only person to comment this. We find that the rule book is…
"We are already well recognized on the market, but we intend reinforce on our status as an innovative company that makes the difference for the patients;…
"The MC Medical may become the future name and future direction of the company. We must implement this change slowly so the people that know us,…
"We are cautiously optimistic and hopeful that the new legislation will be a game-changer for Portugal, shifting the paradigm for patient care. "
"Above all, this is the ultimate goal: nothing else matters more than bringing innovation to patients. When we have the privilege of being able to provide…
"As we approach 2022, we intend to introduce two new therapeutic entities to the market every year. Several in our new therapeutic areas. Lilly plays an…
"Our idea is to have a continuous flow of manufacturing, for example a production area where we produce liquids that flow down to the lower levels,…
The resilience, tenacity, and perseverance required in our teams, that I see on a daily basis at Bial, is another key attribute of Bial’s culture. Without…
We will fuel innovation in the next three years, as we expect to bring 11 new treatments to Portugal in our Pharma portfolio and several new…
